ArticleFrontiers in immunology2022

Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.

Wengang Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.